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Abstract
Resistance to cancer treatment can be driven by epigenetic repro-
gramming of specific transcriptomes in favor of the refractory
phenotypes. Here we discover that tamoxifen resistance in breast
cancer is driven by a regulatory axis consisting of a master transcrip-
tion factor, its cofactor, and an epigenetic regulator. The oncogenic
histone methyltransferase EZH2 conferred tamoxifen resistance by
silencing the expression of the estrogen receptor a (ERa) cofactor
GREB1. In clinical specimens, induction of DNA methylation of a
particular CpG-enriched region at the GREB1 promoter negatively
correlatedwithGREB1 levels and cell sensitivity to endocrine agents.
GREB1 also ensured proper cellular reactions to different ligands by
recruiting distinct sets of ERa cofactors to cis-regulatory elements,
which explains the contradictory biological effects of GREB1 on
breast cancer cell growth in response to estrogen or antiestrogen. In
refractory cells, EZH2-dependent repression of GREB1 triggered
chromatin reallocation of ERa coregulators, converting the anties-
trogen into an agonist. In clinical specimens from patients receiving
adjuvant tamoxifen treatment, expression levels of EZH2 and
GREB1 were correlated negatively, and taken together better pre-
dicted patient responses to endocrine therapy. Overall, our work
suggests a new strategy to overcome endocrine resistance in meta-
static breast cancer by targeting a particular epigenetic program.
Significance: This study suggests a new strategy to over-
come endocrine resistance in metastatic breast cancer by
targeting a particular epigenetic program defined within. Cancer
Res; 78(3); 671–84. 2017 AACR.
Introduction
Tamoxifen, by competing with the hormone estrogen for
binding to the receptor (ERa) in mammary tissues, is one of the
commonly prescribed endocrine agents for both early and
advanced ER-positive (ERþ) breast cancer. Unfortunately, a seri-
ous limitation of this endocrine therapy is the development of
acquired resistance. Substantial evidence suggests that changes of
components along the ERa axis, such as altered expression of ERa
cofactors, may reprogram ERa-mediated transcriptome that
underlie the development of endocrine resistance (1). Recently,
growth regulation by estrogen in breast cancer 1 (GREB1) was
identified as the strongest interactor of estrogen-liganded, but not
tamoxifen-liganded ERa (2). GREB1 enhances ERa-mediated
gene expression and cell proliferation upon estrogen stimulation
(2, 3), but blocks the growth of tamoxifen-resistant (TamR) breast
cancer cells (2). Considering that GREB1 is a critical regulatory
protein of ERa activity and that it exerts differential biological
functions in tamoxifen-sensitive versus tamoxifen-refractory cells,
GREB1–ERa axismayplay apivotal role in determining cell fate in
response to the antiestrogen treatment.
As a highly evolving process, endocrine resistance originates
from a number of mechanisms. One of the critical contributory
factors is the epigenetic alteration occurring at individual driver
genes or even to thewhole transcriptional network (4, 5). Histone
methyltransferase EZH2 has a well-demonstrated role in the
progression of aggressive cancers (6–8). EZH2 methylates lysine
27 on histone H3 and thereby represses transcription of target
genes (9). In addition, EZH2 is shown to directly interact with
DNA methyltransferases and functionally govern DNA methyla-
tion, centering EZH2 at a pivotal position linking two critical
epigenetic programs (10–12). Although roles of EZH2 in driving
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cancer progression are extensively characterized, few studies
investigate the association of EZH2with acquired drug resistance.
In particular, with the small-molecule inhibitors of EZH2 avail-
able (13, 14), it is important to test whether pharmacologic
inhibition of EZH2 will hold promise in the treatment of ther-
apy-resistant cancers.
In this study, we demonstrated that EZH2-mediated epige-
netic silencing of ERa cofactor GREB1, conceivably through
DNA methylation, reprograms ERa-dependent transcriptional
machinery, which leads to the refractory phenotype in breast
cancer cells. We revealed an important transcriptional axis
comprised of ERa, EZH2, and GREB1 in driving the develop-
ment of tamoxifen resistance.
Materials and Methods
Plasmids and siRNAs
Human pLenti-CMV-HA-Hygro-EZH2 was generously provid-
ed by Dr. Lixin Wan (H. Lee Moffitt Cancer Center, Tampa, FL).
EZH2-specific shRNAs were generated as reported previously
(15). Both of shGREB1-1 and -2 (TRCN0000273201 and
TRCN0000000290) were purchased from Sigma, and siGREB1
(M-008187-01-0005) was obtained from Dharmacon.
Antibodies and reagents
Antibodies being used in this study for Western blots include:
anti-GREB1 (#ab72999; Abcam), anti-EZH2 (#612666; BD Bio-
sciences), anti-ERa (#sc-543; Santa Cruz Biotechnology), anti-p300
(#A300-358A; Bethyl Laboratories), anti-CBP (#NB100-382;Novus
Biologicals), anti-NCoR (#ab24552; Abcam), anti-HA (#901501;
Biolegend), anti-H3K27me3 (#9733; Cell Signaling Technology),
anti-GAPDH (#sc-365062; Santa Cruz Biotechnology), and anti-H3
(#ab1791; Abcam). Antibodies for ChIP assays include: anti-ERa
(#sc-543; Santa Cruz Biotechnology and #MS-315; Thermo Scien-
tific), anti-EZH2 (#39933; Active Motif), anti-H3K27me3 (#9733;
Cell Signaling Technology), anti-p300 (#sc-48343X; Santa Cruz
Biotechnology), anti-CBP (#ab2832; Abcam and #sc-7300; Santa
Cruz Biotechnology), and anti-NCoR (#ab24552; Abcam). Anti-
bodies used for IHC staining are mentioned below in the "IHC and
quantification of IHC analysis" section. EZH2 inhibitors were
purchased from Xcess Biosciences Inc. (GSK126, GSK343, and
EPZ-6438). Estradiol (E2), tamoxifen metabolite 4-hydroxytamox-
ifen (4-OHT), and 5-Aza-20-deoxycytidine (5-Aza) were obtained
from Sigma, unless otherwise indicated.
Cell lines and transfection
Paired tamoxifen-sensitive and -resistant MCF-7, ZR-75-1, and T-
47D cellswere generated andprovidedbyDr. Rachel Schiff at Baylor
College ofMedicine (Houston, TX; refs. 16, 17). TheparentalMCF-7
was obtained from Dr. Marc Lippman at the National Cancer
Institute (Bethesda, MD); ZR-75-1 and T-47Dwere purchased from
ATCC. Authenticity of each cell line was confirmed once the resis-
tance to tamoxifen was established. siRNA was transfected using
Lipofectamine 2000 transfection reagent (Invitrogen) following the
manufacturer's instruction. Stable clones were selected and main-
tained in either 2 mg/mL of puromycin (Sigma) for shRNAs or 200
mg/mL of Hygromycin B (Sigma) for EZH2 overexpression.
Quantitative RT-PCR
Total RNA was isolated using TRIzol Reagent (Invitrogen) and
subjected to RT-PCR using High-Capacity cDNA Reverse Tran-
scription Kit (Thermo Fisher Scientific). Gene expression was
calculated as described previously (15), and primers used for
qPCR are listed in the Supplementary Table S1.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) was performed as
described previously (15). Quantitative PCR was then performed
with specific primers of targeted sites, the sequences of which are
listed in Supplementary Table S2. Details are described in the
Supplementary Materials and Methods.
RNA-Seq data analysis
RNA-Seq libraries were constructed using TruSeq RNA Sample
Prep Kit v2 (Illumina, #RS-122-2001), and then sequenced on
HiSeq 3000 at Genome Sequencing Facility of The University of
Texas Health Science Center at San Antonio (UTHSCSA, San
Antonio, TX). The sequencing reads were aligned to human
genome (hg19) using TopHat 2.0.10 (Bowtie2 2.1.0), and edgeR
3.12.1 was used to call differentially expressed genes. Data anal-
yses were detailed in the Supplementary Materials and Methods.
Gene signature definition
Genes differentially expressed upon silencing of EZH2 were
overlapped with chemical and genetic perturbations (CGP) gene
sets from C2-curated category in MSigDB dataset collection (18).
The P values were calculated on the basis of the hypergeometric
distribution, and the top 100 enriched gene sets were selected for
the following analysis. To determine the gene signatures that were
coregulated by EZH2 and ERa signaling, ERa-dependent core
genes were first defined by the following two criteria: (i) expres-
sion of these genes were significantly changed upon E2 stimula-
tion, and (ii) each gene contains at least one ERa binding peak
within 30 kb from its transcription start site (TSS) in MCF-7 cells.
ERa ChIP-Seq data were retrieved from GSE25710 (19), and
binding peaks were called by MACS with default parameters
(20). Genes that were shared between ERa-dependent core genes
and EZH2-regulated ones were identified as the signature genes
that are controlled by both EZH2 and ERa signaling.
Patient information
In this study, 130 paraffin-embedded tissue samples were
included and collected from patients with ERa-positive, stage
0–II breast cancer. Patient cohorts for IHC staining, tumor spec-
imen collection, survey data, and all clinical and pathologic
information were reviewed and approved by the Review Board
on Human Research of Universidad de La Frontera, Hospital de
Temuco (Chile). Protocols of the studywere approvedby theEthic
Committees of the participating institutions (Universidad de la
Frontera and Instituto de Biología yMedicina Experimental). This
study was conducted under the provisions of the Declaration of
Helsinki and informed written consents were obtained from all
patients before inclusion. Pretreatment staging of the selected
patientswas classified according to theAmerican JointCommittee
on Cancer (AJCC) staging system (21) and the Elston and Ellis
histologic grading system (22). Clinical pathologic data of the
cohorts are shown in Supplementary Table S3.
IHC analysis and quantification
Paraffin-embedded breast cancer samples from patients and
xenograft tumors were subjected to IHC staining with primary
antibodies as follows: EZH2 (dilution 1:200; #NCL-L-EZH2;
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Novocastra), GREB1 (dilution 1:400; #MABS62; EMDMillipore),
ERa (dilution 1:75; #NCL-L-ER-6F11; Novocastra), Ki67 (dilu-
tion 1:400; #9027; Cell Signaling Technology), and cleaved
caspase-3 (dilution 1:100, #9661S; Cell Signaling Technology).
The expression levels of EZH2, GREB1, and ERa were assessed
using a combination of both intensity and proportion of stained
cells with different criteria according to the method described
previously, respectively (2, 23–25). Details of quantification of
staining are described in the Supplementary Materials and
Methods.
For correlation analysis, all the samples were stratified into
three groups based on IHC scores of either EZH2 or ERa (low,
scores of EZH2 3 or scores of ERa ¼ 1; medium, 3< scores of
EZH26or scores of ERa¼2; high, scores of EZH2>6or scores of
ERa ¼ 3). Afterwards, the distribution of each GREB1 IHC score
within one particular group was calculated. P values were
obtained by Fisher exact analysis.
DNA methylation data analysis and pyrosequencing assay
Illumina HumanMethylation450K BeadChip data for paren-
tal MCF-7 and three MCF-7-derived, endocrine-resistant cell
lines were retrieved from GSE69118 (26). Raw data were
preprocessed and background normalized with the Bioconduc-
tor package minfi as described previously (27). Genome-wide
DNA methylome in TCGA was retrieved from Firehose (28).
Only those samples that were collected from ERþ patients and
have both DNA methylation and mRNA-Seq data available
were retained. Any methylation probes with more than 50
missing data were excluded.
Distribution of the pathologic stages of breast cancer in TCGA
cohort regarding the involvement of regional lymph nodes was
plotted on the basis of the average methylation levels at three
probes that show the strongest negative correlation with GREB1
expression. Patients were stratified into four groups according to
the average methylation levels at those three probes, distribution
of each pathologic staging classification among these groups was
then compared using Fisher exact test.
Five-hundred nanograms of genomic DNA per sample was
bisulfite converted using the EZ DNA Methylation Kit (Zymo
Research) according to the manufacturer's instruction. The
methylation levels were quantified by the PyroMark Q96 MD
System at the Bioanalytics and Single-Cell Core (BASiC) of
UTHSCSA. The methylation percentage of each interrogated
CpG site was calculated by PyroMark CpG software
(Qiagen). Details of primer sequence and pyrosequencing
assay are described in the Supplementary Materials and
Methods.
In vivo studies
All the animal work was performed with the approval of
UTHSCSA Institutional Animal Care Committee and the animals
were handled in accordancewith institutional andnational guide-
lines for animal experiments. Briefly, 5  106 TamR MCF-7 cells
were mixed with equal volume of Matrigel (Thermo Fisher Sci-
entific), and then injected subcutaneously into the inguinal
mammary fat pads of 6-week-old female nude mice (Charles
River) at both sides. Estrogen pellets (Innovative Research, 0.72
mg 60-day release) were implanted on the same day of cell
inoculation. When tumors reached the volume of approximately
200–300 mm3, mice were randomly assigned into either treat-
ment group or control group. 4-Hydroxytamoxifen (Tocris Bio-
science) was given subcutaneously at a dose of 100 mg per mouse
every day. The powder of EZH2 inhibitors was dissolved in 20%
captisol (CyDex Pharmaceuticals, Inc.). GSK126 was adminis-
tered intraperitoneally while EPZ-6438 was by oral gavage. Both
drugs were delivered either daily for 5 days per week at 50 mg/kg
dose or twice perweek at 300mg/kg dose. The captisol vehiclewas
administered into the control animals with the same volume of
200 mL per mouse. Tumor sizes were measured with calipers and
bodyweights weremonitored twice weekly throughout the exper-
iment. Tumors from each group were harvested after 35 days of
treatment, and then snap frozen in liquid nitrogen orfixed in 10%
formalin for downstream studies.
Accession number
The RNA-Seq data of EZH2 knockdown in TamR MCF-7 cells
and EZH2 overexpression in MCF-7 cells were deposited at the
Gene Expression Omnibus database with an accession number
GSE103243.
Results
EZH2 renders tamoxifen resistance in breast cancer cells
In the publicly available gene expression datasets from ERþ
breast cancer patients who received tamoxifen as an adjuvant
treatment (29, 30), we observed a dramatic increase of EZH2
transcript level in clinical samples that are resistant to tamox-
ifen compared to the sensitive ones (Fig. 1A; Supplementary
Fig. S1A). Higher level of EZH2 was significantly associated
with poorer disease-free survival in these patients (Fig. 1B;
Supplementary Fig. S1B). These results suggest that EZH2 may
play an important role associated with drug resistance in breast
cancer.
To explore the exact biological effects of EZH2 in acquired
treatment resistance, we overexpressed EZH2 in tamoxifen-
sensitive, ERþ breast cancer MCF-7 cells (Fig. 1C) or knocked
down EZH2 in MCF-7–derived, TamR cells (Fig. 1D), and then
measured cellular response to increasing concentrations of 4-
hydroxytamoxifen (4-OHT), the active metabolite of the anties-
trogen. Although overexpression of EZH2 led to decreased sen-
sitivity of MCF-7 to tamoxifen (Fig. 1C), depletion of EZH2
attenuated the agonistic effect of tamoxifen on TamR cell prolif-
eration (Fig. 1D). This result was also confirmed in TamR coun-
terpart of another ERþ breast cancer cell line, TamR ZR-75-1
(Supplementary Fig. S1C). Collectively, these results indicate that
EZH2 is essential for conferring tamoxifen resistance and repre-
sents a promising therapeutic target. Therefore, we tested two
EZH2 inhibitors (GSK343 andEPZ-6438) that selectively block its
methyltransferase activity in three ERþ TamR breast cancer cell
lines (TamRMCF-7, TamR ZR-75-1, and TamR T-47D) and found
that both drugs dramatically suppressed cell growth (Fig. 1E;
Supplementary Fig. S1D and S1E), suggesting that inhibition of
EZH2 enzymatic activity is a putative approach to treating endo-
crine therapy–resistant breast cancer.
EZH2 orchestrates an ERa-dependent transcriptional
program in favor of endocrine resistance
The role of EZH2 in controlling cell sensitivity to tamoxifen
made us wonder whether ERa activity in the presence of
tamoxifen could be regulated by EZH2. To this end, we per-
formed RNA-Seq after knocking down EZH2 in TamR MCF-7
cells. Gene set enrichment analysis (GSEA) of genes that were
EZH2 Drives Tamoxifen Resistance via GREB1 DNA Methylation
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differentially expressed upon EZH2 silencing revealed that ERa-
regulated genes were significantly enriched (Fig. 2A). To our
surprise, when we compared these EZH2-dependent genes with
those differentially expressed upon hormone treatment in
MCF-7, we found that EZH2 depletion in TamR cells resulted
in a transcriptional profile highly similar to the gene expression
pattern prompted by tamoxifen in parental cells (Fig. 2B). This
intriguing observation indicates that loss of EZH2 switches the
transcriptional regulatory network in TamR MCF-7 cells back to
the one sensitive to the antiestrogen. To further prove the
conclusion, gene expression profiling was also carried out in
EZH2-overexpressing MCF-7 cells (Fig. 2C). Interestingly,
responses of tamoxifen-regulated genes to the endocrine agent
were all alleviated, or say muted, when EZH2 was overex-
pressed (Fig. 2C; Supplementary Fig. S2A), suggesting that
overabundance of EZH2 makes tamoxifen-sensitive breast can-
cer cells refractory to the drug. In addition, we found gene
signatures that are involved in endocrine resistance develop-
ment were highly represented in the functional categories of
EZH2-regulated genes (Fig. 2D), especially those that were
upregulated upon EZH2 knockdown (Supplementary Fig.
S2B), highlighting the transcriptional repression function of
EZH2 in endocrine resistance.
To elucidate how EZH2 functionally regulates ERa activity
responding to tamoxifen precisely, we detected the expression
changes of four classical ERa target genes upon modulation of
EZH2 levels in the presence of 4-OHT. Expression of these ERa
targets was no longer inhibited, or even increased, when EZH2
was overexpressed in MCF-7 (Fig. 2E), although was suppressed
upon EZH2 silencing in the resistant TamR cells (Fig. 2F) by
tamoxifen. ERa binding to the cis-regulatory elements near these
ERa targets was somewhat increased or generally comparable
when EZH2was overexpressed (Fig. 2G; Supplementary Fig. S3A)
or knocked down (Fig. 2H; Supplementary Fig. S3B). Interesting-
ly, inMCF-7 cellswith overabundanceof EZH2, the recruitment of
ERa coactivators p300 and CBP were significantly elevated, and
the binding of NCoR, a corepressor thatmediates the antagonistic
effects of tamoxifen (31), was dramatically decreased (Fig. 2G;
Supplementary Fig. S3A). In contrast, in TamR MCF-7 that was
depleted of EZH2, recruitment of p300 and CBP to these ERa
target loci was diminished, whereas NCoR bound with much
stronger intensities (Fig. 2H; Supplementary Fig. S3B). All of these
results indicate that EZH2 reprograms an ER-dependent transcrip-
tional network that retains transactivation functioning even in the
presence of tamoxifen. However, occupancy of ERa and its
coregulators at ERa-binding elements near E2-stimulated genes
that were not regulated by EZH2 were similar or marginally
changed, no matter how EZH2 protein levels were manipulated
(Supplementary Fig. S3C and S3D). This result suggests that EZH2
regulates the functional composition of ERa-associated transcrip-
tional complex at specific ERa-bound regulatory regions rather
than in a global, general way. Transcript levels of ESR1, p300, CBP,
Figure 1.
EZH2 confers tamoxifen resistance in breast cancer cells. A and B, Comparison of EZH2 mRNA level in breast tumors according to their sensitivities to
tamoxifen (A) and Kaplan–Meier analysis (B) of disease-free survival based on EZH2 mRNA levels using GSE9195 cohort (29). Tam-R, tamoxifen-resistant;
Tam-S, tamoxifen-sensitive. Red curve, top 50% with high EZH2 level; blue curve, bottom 50% with low EZH2 level. N in brackets, number of patients in each
specific group. P value was calculated by Mann–Whitney test (A) and log-rank test (B). C and D, Responses to tamoxifen in originally sensitive MCF-7 cells
upon no transfection (MCF-7), stably expressing either empty vector (MCF-7-EV) or HA-tagged EZH2 (MCF-7-EZH2; C) and in TamR MCF-7 cells with EZH2
depletion using two independent shRNAs (shEZH2-1 and -4; D). Cell numbers were counted after 7 days of incubation with indicated concentrations of
4-OHT. Left, Western blot analysis of total cell lysates with indicated antibodies. E, Inhibitory effect of EZH2 inhibitors (GSK343 and EPZ-6438) on
proliferation of TamR MCF-7 cells. Cells were maintained in 100 nmol/L 4-OHT and treated with DMSO (Veh.), 5 mmol/L GSK343 or EPZ-6438, then collected
at indicated time points for cell counting. Left, Western blot analysis of total cell lysates and nuclear extract. Data were presented as mean  SEM of
triplicates.  , P < 0.05; , P < 0.001, and P values in C–E were calculated by two-tailed t test.
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Figure 2.
EZH2 regulates an ERa-associated transcriptional profile in favor of endocrine resistance. A, GSEA analysis of differentially expressed genes upon EZH2
knockdown in TamR MCF-7 cells. P values were determined by Kolmogorov–Smirnov test. B, Unsupervised hierarchical cluster analysis of genes that
were changed when MCF-7 was treated with E2 (E2 vs. Veh.) or E2 plus 4-OHT (E2 þ 4-OHT vs. E2) using GSE25316 dataset (19) and genes that are
differentially expressed upon EZH2 knockdown in TamR MCF-7 cells (shEZH2 vs. shCtrl). Color scale bar indicates the log2 of differential gene expression from
the lowest (blue) to the highest (red) level. C, Scatter plot showing transcriptional changes of tamoxifen-regulated genes upon the antiestrogen
treatment (fold change  1.5, Padj < 0.05) in either control cells (x-axis) or EZH2-overexpressing MCF-7 cells (y-axis). D, Functional annotations of
EZH2-regulated genes in TamR MCF-7 cells. Annotations that are associated with endocrine therapy resistance were highlighted in red. Blue bar, numbers
of genes overlapped within each indicated gene set; red line, adjusted P value of each functional category. E and F, Quantitative RT-PCR showing
expression changes of ERa target genes in MCF-7 cells upon EZH2 overexpression (E) and TamR MCF-7 cells upon EZH2 depletion (F) with the treatment
of either ethanol (Veh.) or 100 nmol/L 4-OHT for 6 hours. G and H, ChIP-qPCR results at cis-regulatory elements near XBP1 gene in EZH2-overexpressing
MCF-7 cells (G) and EZH2-silenced TamR MCF-7 cells (H) with the treatment of 1 mmol/L 4-OHT for 45 minutes. Data were plotted as means  SEM of
replicates after being normalized to GAPDH (mRNA) or KIAA0066 (ChIP-qPCR) as the internal control.  , P < 0.05 and  , P < 0.001 by two-sided t test.
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and NCoR were controlled by neither tamoxifen treatment nor
EZH2 (Supplementary Fig. S4A and S4B). Protein levels of these
transcription (co)factors were marginally altered as well, except
that p300 and CBP proteins seemed to be increased upon EZH2
knockdown in the presence of 4-OHT (Supplementary Fig. S4C).
Collectively, these findings indicate that EZH2 recomposes an
ERa-centered transcriptional complex in the presence of tamox-
ifen and therefore reprograms the ERa-dependent gene expres-
sion profiles, which potentially leads to the refractory phenotype
in breast cancer cells.
EZH2 epigenetically silences ERa cofactor GREB1
Our above analysis indicates that EZH2 renders tamoxifen
resistance by regulating ERa activity in response to the antag-
onist. Because ERa protein was barely changed upon manip-
ulation of EZH2 level or enzymatic activity, this raises the
possibility that EZH2 may actually modulate an ERa-regulatory
protein that controls cell response to tamoxifen. Thus, we first
defined a list of genes that are regulated by EZH2 and estradiol,
contain at least one ERa binding peak around their TSSs and are
functionally related to endocrine resistance. 43 genes were thus
filtered out, and expression of each individual gene was asso-
ciated with tamoxifen responses in clinical samples by receiver
operating characteristic (ROC) curve analysis (29, 30). As a
control, EZH2 was spotted as the gene that is most significantly
linked to tamoxifen resistance. Interestingly, one of the top
upregulated genes upon EZH2 knockdown showing close cor-
relation with tamoxifen sensitivity is GREB1 (Fig. 3A), a well-
known ERa cofactor (2). Similar result was obtained when all
genes that were silenced by EZH2 were considered (Supple-
mentary Fig. S5A).
To test whether GREB1 is an EZH2-dependent target gene, we
first knocked down EZH2 in TamR MCF-7 cells and detected a
dramatic elevation of GREB1 at both transcript (Fig. 3B) and
protein (Fig. 3C) levels. This result was further confirmed in
TamR ZR-75-1 cells (Supplementary Fig. S5B and S5C). GREB1
protein was drastically increased upon the treatment of EZH2
inhibitors GSK343 and EPZ-6438 in all of the three tamoxifen-
resistant cell lines we have (Supplementary Fig. S5D). It is
notable that ERa levels were not significantly affected under
any of the experimental conditions (Fig. 3B and C; Supple-
mentary Fig. S5B–S5D). This implies that EZH2-mediated
repression of GREB1 expression may be attributed to the
enzymatic activity of the epigenetic regulator.
Therefore, we examined H3K27 trimethylation (H3K27me3)
signal at GREB1 promoter. EZH2 knockdown in TamR MCF-7
cells significantly diminished the intensity of H3K27me3 at two
separate locations around GREB1 TSS (Supplementary Fig. S6A).
Decrease of H3K27me3 levels was also noticed near other EZH2-
repressed genes in TamR cells upon EZH2 depletion (Supple-
mentary Fig. S6B), suggesting that EZH2 is fully functional
concerning regulation of the epigenetic mark H3K27me3. How-
ever, occupancy of both EZH2 and H3K27me3 were weak at
GREB1 promoter compared with well-characterized target locus
such as WNT1 promoter (Supplementary Fig. S6C; ref. 32) and
the intensities of H3K27me3 were comparable between TamR
and parental MCF-7 cells (Supplementary Fig. S6C). These
results indicate that H3K27me3 may not be the predominant
epigenetic mark contributing to EZH2-mediated silencing of
GREB1 in endocrine-resistant breast cancer cells. Considering
an important role of EZH2 in dictating DNA methylation, we
next examined whether methylation of any CpG sites at GREB1
promoter is functionally important and can be modulated by
EZH2. We first retrieved genome-wide methylation profiles in
MCF-7 and three different endocrine-resistant counterpart cell
lines (26), and then inspected the DNA methylation levels near
or within GREB1 gene. Strikingly, we located a CpG-containing
area at GREB1 promoter showing remarkably strong methyla-
tion in all of these three endocrine-resistant cells, but very
minimal signals in the parental MCF-7 (Fig. 3D, top). When
we examined the DNA methylation pattern of the entire GREB1
gene in TCGA methylome data from ERþ breast cancers (28),
we found that DNA methylation signals at this particular locus
showed strong negative correlation with GREB1 expression
(Fig. 3D, middle). More interestingly, we obtained a significant,
positive association between pathologic statuses concerning
nearby lymph node involvement, one of the most informative
factors evaluating tumor progression, and DNA methylation
signals at the subloci that show the strongest negative correla-
tion with GREB1 levels (Fig. 3D, bottom). Moreover, the tran-
script level of GREB1 was significantly decreased in patients'
samples resistant to tamoxifen therapy in two independent
cohorts (Supplementary Fig. S6D and S6E), which was notably
associated with poorer disease-free survival (Supplementary
Fig. S6F and S6G). Taken together, these results suggested the
important role of GREB1 in endocrine resistance, which may be
attributed to DNA methylation at its promoter region.
We next asked whether EZH2 could control DNA methyla-
tion at this specific site. Pyrosequencing analysis showed a
significant decrease of DNA methylation in TamR MCF-7 cells
upon EZH2 knockdown compared with the control (Fig. 3E).
Similarly, EZH2 overexpression in the parental MCF-7 cells
induced nearly 2-fold increase in DNA methylation signals at
GREB1 promoter region, although it was not statistically sig-
nificant possibly due to the extremely low basal methylation
signal (Supplementary Fig. S6H). Furthermore, EZH2 overex-
pression–induced silencing of GREB1 gene in MCF-7 cells was
relieved by the DNA methyltransferase (DNMT) inhibitor 5-
Aza-20-deoxycytidine (5-Aza; Fig. 3F), whereas EZH2 depletion
plus 5-Aza treatment in TamR cells led to the most dramatic
increase in GREB1 mRNA levels (Fig. 3G). All these results
indicate that EZH2-mediated suppression of GREB1 expression
is conceivably mediated through DNAmethylation. It is worthy
of note that our gene expression profiling in TamR MCF-7 cells
identified DNA methyltransferases DNMT1 and 3B as two
significantly downregulated genes upon EZH2 depletion (Sup-
plementary Fig. S6I). This may give an explanation for the
dependency of DNA methylation signals on EZH2 at GREB1
promoter region.
GREB1 recomposes ERa-associated transcriptional complexes
responding to different ligands
We then sought to understand the exact role of GREB1 in
orchestrating ERa activity in response to the antiestrogen. GREB1
was silenced in MCF-7 cells treated with estradiol and/or 4-OHT
(Fig. 4A). Efficient knockdown of GREB1 drastically decreased
E2-stimulated expression of ERa target genes (Fig. 4B). This is in
line with previous report that GREB1 is essential for estrogen-
specific activation of ERa signaling (2). In contrast, expression of
these genes was no more suppressed and even enhanced by
tamoxifen when GREB1 was depleted (Fig. 4B).
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It has been reported that GREB1 conciliates interaction
between ERa and other cofactors at targeted cis-regulatory
chromatin regions (2), so we next investigated whether GREB1
modulates the hierarchical structures of ERa-associated tran-
scriptional complex responding to different ligands. Upon
estradiol treatment, recruitment of ERa coactivators p300 and
CBP were dramatically decreased by GREB1 depletion, which is
in agreement with published data (Fig. 4C; ref. 2). In the
Figure 3.
EZH2 epigenetically silences GREB1 expression via DNA methylation. A, ROC curve analysis indicating the correlation of EZH2-regulated genes that are involved in
ERa signaling with tamoxifen responses in GSE9195 and GSE12093 cohorts (29, 30). Blue dots, EZH2-repressed genes; red dots, EZH2-activated genes.
B and C, Upregulation of GREB1 at both mRNA (B) and protein (C) levels upon shEZH2 in TamR MCF-7 cells. D, Clinical relevance of DNA methylation at a specified
areawithinGREB1 promoter. Top, duplicates of DNAmethylation profiling in MCF-7 cells and three distinct endocrine-resistant, MCF-7–derived cell lines (26). TamR,
tamoxifen-resistant; MCF7X, estrogen deprivation resistant; FASR, fulvestrant resistant. Location of the CpG sites displaying differential patterns is highlighted in
gray.Middle, heatmapdepicting the correlation ofDNAmethylation signals at each specifiedprobe for every single patientwithGREB1 expression in TCGAdata (28).
Bottom, correlation between themethylation levels of the underlined probeswith pathologic stages concerning the involvement of regional lymph node.P valuewas
calculated by Fisher exact test. E, Decrease in DNA methylation intensity at GREB1 promoter region upon EZH2 depletion in TamR MCF-7 cells. Pyrosequencing
was performed at locus highlighted in D. F, Restoration of EZH2 overexpression-induced repression of GREB1 expression by 5-Aza. Control (EV) or EZH2-
overexpressing (EZH2) MCF-7 cells were treated with DMSO (Veh.) or increasing concentrations of 5-Aza (1, 5, and 10 mmol/L) for 72 hours. G, RT-qPCR showing
transcript levels of GREB1 and ESR1 upon EZH2 knockdown with or without 5-Aza treatment. Stable TamR MCF-7 clones were treated with DMSO (Veh.) or 5-Aza
(5 mmol/L) for 120 hours. Data are presented as means  SEM of replicates.  , P < 0.05 and  , P < 0.001 by two-sided t test.
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presence of 4-OHT, however, silencing of GREB1 led to signif-
icantly increased intensity of p300 and CBP at these ERa
binding. Coincidentally, the presence of NCoR was diminished
(Fig. 4C). All these results suggest a novel and critical function
of GREB1 in refining proper compositions of ERa-centered
transcriptional complexes in response to different ligands.
Functionally, knockdown of GREB1 in MCF-7 impaired E2-
stimulated cell growth, but reversed the inhibitory effect of 4-
OHT and even promoted cell proliferation in the presence of
the antiestrogen (Supplementary Fig. S7A). As such, GREB1-
depleted MCF-7 cells survived after 7 days of incubation with 4-
OHT even at concentration as high as 5 mmol/L, under which
condition the control cells stopped growing and underwent
apoptosis (Supplementary Fig. S7B).
Next we asked whether the role of EZH2 in recomposing ERa-
centered transcriptional complex in response to tamoxifen is
actually mediated by the modulatory function of GREB1 on ERa
activity. Therefore, we knocked down GREB1 in EZH2-depleted
TamR MCF-7 cells by two independent shRNAs against GREB1
(Fig. 4D, bottom). We first examined how cells responded to
tamoxifen. As what we observed previously, knockdown of EZH2
alone abolished the stimulating effect of tamoxifen on cell growth
(Figs. 1D and 4D; Supplementary Fig. S1C). When GREB1 was
depleted simultaneously, however, the double-knockdown cells
became refractory to tamoxifen again (Fig. 4D, top). At selected
ERa-binding sites, EZH2 depletion led to decreased intensities of
p300 and CBP but increased recruitment of NCoR in TamR cells
(Fig. 4E). However, chromatin binding of these regulatory
Figure 4.
GREB1 blocks the activation of tamoxifen-liganded ERa. A and B, Alleviation of the inhibitory effects of tamoxifen on ERa activity upon GREB1 knockdown.
Upon transient transfection with control siRNA (siCtrl) or siRNA pool targeting GREB1 (siGREB1), MCF-7 cells were hormone deprived for 3 days and
then treated with ethanol (Veh.), 10 nmol/L E2, or 10 nmol/L E2 plus 100 nmol/L 4-OHT for 6 hours. Total cell lysates were prepared for immunoblotting (A) or
total RNA was subjected to qRT-PCR (B). mRNA levels were normalized to GAPDH and are presented as mean  SEM of replicates. C, Binding of ERa
coregulators near target genes in GREB1-depleted breast cancer cells. GREB1 was silenced in MCF-7 cells by two independent shRNAs (shGREB1-1 and
shGREB1-2), and the stable clones were treated with ethanol (Veh.), 100 nmol/L E2, or 1 mmol/L 4-OHT for 45 minutes after hormone deprivation for 3 days.
Quantitative PCR was performed and are presented as mean  SEM of replicates. D, Essential role of GREB1 in mediating the effects of EZH2 on
conferring resistance to tamoxifen. Stable clones of EZH2-depleted (shEZH2) TamR MCF-7 cells were infected with two independent shGREB1 and
treated with 4-OHT at indicated concentrations for 7 days before cell numbers were counted. Bottom, Western blot analysis confirming the knockdown
efficiencies of shEZH2 and shGREB1. Statistical difference was calculated in comparison with the data from EZH2-depleted cells. E, ChIP-qPCR showing
reverse of EZH2 depletion-induced chromatin redistribution of ERa coregulators upon GREB1 knockdown. Data are presented as mean  SEM of triplicates.  ,
P < 0.05 and , P < 0.001 by two-tailed t test.
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proteins reversed back to the original levels when GREB1 was
concurrently depleted. Notably, binding intensities of p300 and
CBP at the selected sites were in general higher when both EZH2
andGREB1were knocked down than in the control cells (Fig. 4E),
which may be explained by the increased protein levels of p300
and CBP upon 4-OHT treatment in EZH2-depleted TamR cells
(Supplementary Fig. S4C). These results suggest that reprogram-
ming of ERa-involved transcriptional network in resistant cells,
which is orchestrated by EZH2, requires the maintenance of
GREB1 protein at low levels. Otherwise, GREB1 reallocates ERa
cofactors to cis-regulatory elements to ensure proper inactivation
of ERa signaling responding to the antiestrogen.
Pharmacologic inhibition of EZH2 retarded the growth of
xenograft tumors in TamR mouse model
To explore the translational potential of our findings, we
evaluated the efficacy of two EZH2 inhibitors, GSK126 and
EPZ-6438 (13, 33), in a TamR xenograft mouse model. Both
EZH2-targeting compounds started to suppress the sizes of
TamR MCF-7 xenograft tumors markedly after 2 weeks of
administration, and retained the inhibitory effects throughout
the entire treatment period (Fig. 5A). No differences in animal
body weights were observed between control and treatment
groups, indicating that GSK126 and EPZ-6438 were well tol-
erated by mice (Fig. 5B). A histopathologic characterization of
the xenograft tumors showed a decreased Ki67 labeling and
relatively higher signal of cleaved caspase-3 in tumors from
treatment groups, implying a reduced proliferation rate and
potentially enhanced apoptosis (Fig. 5C). Immunoblot analysis
of extracts from four independent xenograft tumors in either
control or treatment groups confirmed that GREB1 protein was
notably elevated by EZH2 inhibitors, whereas ERa and EZH2
were marginally changed (Fig. 5D, top). The result was better
illustrated by the quantification of each protein level in
Figure 5.
Pharmacologic inhibition of EZH2 represents a promising therapeutic strategy for TamR breast cancer. A, Efficacy of EZH2 inhibitors on the growth of
TamR xenograft tumors at the indicated dose for a course of 35 days. Data are presented as mean tumor volume  SEM. B, Effects of EZH2 inhibitors on body
weights of mice receiving the treatment. Data are presented as mean  SEM. C, Characterization of TamR MCF-7 xenograft tumors with histologic
analysis by hematoxylin and eosin (H&E) staining and IHC staining of Ki67 and cleaved caspase-3. Scale bars, 100 mm. D, Western blot analysis of indicated
proteins in TamR xenograft tumors. Bottom, quantitative densitometry of protein levels of GREB1, EZH2, and ERa. Number 1–12, numbers of randomly
selected xenograft tumors with four individual samples per group. Data are presented as mean  SEM.  , P < 0.05 and  , P < 0.01 by two-sided t test.
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quadruplicate samples (Fig. 5D, bottom). Taken together, these
results suggest that EZH2 serves as a promising therapeutic
target for TamR breast cancer and that pharmacologic inhibi-
tion of EZH2 potentially leads to derepression of GREB1
expression.
EZH2 and GREB1 negatively correlate with each other in
ERa-positive breast cancer
Next we examined the association between levels of EZH2
and GREB1 in clinical scenarios. First, we correlated the
expression of these two genes in transcriptional profiles from
ERþ breast cancer patients (28). We found that mRNA levels of
GREB1 and EZH2 are inversely correlated, which became more
prominent and significant when more percentages of samples
expressing high levels of EZH2 were considered in the analysis
(Fig. 6A). We then investigated the protein levels of EZH2 and
GREB1 by IHC analysis in clinical tissues collected from ERþ
patients receiving adjuvant tamoxifen therapy. EZH2, GREB1,
and ERa were specifically stained in tamoxifen-sensitive (n ¼
108) and TamR (n ¼ 22) breast tumors, and the tissues were
classified into four groups based on the staining intensities of
EZH2 and GREB1 (Fig. 6B). Specificity of GREB1 antibody
that was used for IHC analysis was validated in both MCF-7
cells and breast tumors (Supplementary Fig. S7C and S7D).
Nuclear staining was predominantly observed, which was
specifically diminished upon GREB1 silencing (Supplemen-
tary Fig. S7C) or in TamR samples (Supplementary Fig. S7D).
These results prove that the signals this antibody recognizes
Figure 6.
Negative correlation between EZH2 and GREB1 in ERþ breast cancer samples receiving tamoxifen as adjuvant treatment. A, Correlation between
EZH2 and GREB1 transcript levels in patient samples. The black curve shows the correlation coefficients and the red shows the P value. The
dotted red line represents P ¼ 0.05. B, IHC staining showing nuclear staining of EZH2, GREB1, and ERa levels in representative ERþ breast tumors.
Scale bar, 50 mm. C, Correlation between EZH2 and GREB1 protein levels based on their IHC scores. P values were calculated using x2 analysis.
D, Percentages of each GREB1 IHC score within the specific groups of samples that are stratified on the basis of either EZH2 (left) or ERa (right) IHC
scores. Med, medium. P values were calculated using Fisher exact analysis. E, Quantification of EZH2, GREB1, and ERa IHC staining in tamoxifen-sensitive
and TamR breast cancer patients. N in brackets, number of patients in each specific group. P values were determined by two-tailed Mann–Whitney test.
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are indicative of a proper GREB1 isoform functioning as an
ERa cofactor (2, 34). It is noteworthy that ERa levels were
comparable among all the groups (Fig. 6B). In EZH2-positive
breast tumors, strikingly more (74.7% vs. 25.3%) specimens
showed negative status of GREB1 protein, whereas in tumors
with no or weak expression of EZH2, more (72.7% vs. 27.3%)
samples exhibited positive staining of GREB1 (Fig. 6C). This
suggests a significant inverse correlation between these two
proteins (P ¼ 8.22E08; Fig. 6C). When we stratified the
patient samples according to EZH2 or ERa protein levels, we
found significantly more percentages of cases showing medi-
um to strong staining of GREB1 when levels of EZH2 were
low, whereas no to weak staining signals of GREB1 in samples
with abundant EZH2 protein (Fig. 6D). Intriguingly, there was
no such obvious correlation between ERa and GREB1 levels
based on their IHC scores (Fig. 6D). All the data indicate
that EZH2 and GREB1 are negatively correlated with each
other in ERþ breast cancer and that ERa may not be involved
in EZH2-mediated repression of GREB1. Besides, in refractory
breast tumors compared with the sensitive ones, EZH2 is
dramatically upregulated (P ¼ 0.026). Although not signifi-
cant (P ¼ 0.117), GREB1 is markedly decreased. Again, ERa is
equally expressed between responsive and resistant groups (P
¼ 0.68; Fig. 6E). In summary, our results confirmed a strong
negative correlation between EZH2 and GREB1 in clinical
tumor samples, which may be firmly associated with cancer
cell fate responding to tamoxifen.
Gene signature regulated by the ERa–EZH2–GREB1 axis
represents a powerful predictive factor for the benefit of
tamoxifen treatment in ERþ breast cancer
We next stratified clinical follow-ups based on EZH2 and
GREB1 levels (Fig. 7A). The tumors that were EZH2 positive and
GREB1 negative had the worst clinical outcome of all (log-rank
test P ¼ 7.8E6; Fig. 7A). We came to the same conclusion when
we associated the clinical data with our IHC results (Fig. 7B). All
these analyses indicate that combination of both EZH2 and
GREB1 levels powerfully predicts breast cancer patients' responses
to tamoxifen.
To further investigate the clinical significance of this gene-
regulatory network consisting of EZH2, ERa, and GREB1, we
defined gene signatures that were coregulated by EZH2 and ERa
Figure 7.
EZH2-mediated regulation of ERa signaling is highly clinical relevant to tamoxifen response. A and B, Kaplan–Meier curve showing disease-free survival
rates in ERþ breast tumors according to both EZH2 and GREB1 levels using GSE9195 and GSE12093 datasets (refs. 29, 30; A) and in 130 ERþ breast
cancer samples for IHC staining (B). þ/, expression level of top 50% (þ) or bottom 50% () of the gene. C and D, Expression levels of gene signature
that is repressed by EZH2 and involved in ERa signaling in tamoxifen-sensitive (Tam-S) or tamoxifen-resistant (Tam-R) breast tumors (C) and their prognostic
power (D) using GSE9195 cohort (29). Figure legends represent the same meaning as in Fig. 1A and B. E, Model depicting the development tamoxifen
resistance driven by the EZH2–ERa–GREB1 transcriptional axis. T, tamoxifen; Me, methylation.
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signaling, and evaluated their therapeutic implications in two
independent cohorts (29, 30). Interestingly, ERa target genes
that are repressed by EZH2 were generally expressed at signif-
icantly lower levels in TamR breast cancer (Fig. 7C; Supple-
mentary Fig. S8A), and their levels were positively associated
with an improved disease-free survival (Fig. 7D; Supplementary
Fig. S8B). However, genes that were dependent on ERa activity
and simultaneously activated by EZH2 did not exhibit clear
expression pattern or significant prognostic power in either
dataset (Supplementary Fig. S8C–S8F). These results suggest
that function of EZH2 as a transcriptional repressor dominates
its biological role in conferring tamoxifen resistance in breast
cancer cells. This also perfectly fits with our GSEA analysis of
EZH2-regulated genes showing that functional annotations
associated with endocrine resistance were only enriched in
EZH2-repressed genes (Supplementary Fig. S2B). Therefore,
targeting the ERa–GREB1–EZH2 axis holds promise for over-
coming this major clinical challenge in the management of
endocrine therapy–resistant ERþ breast cancer.
Discussion
In ERþbreast cancer, tamoxifen andother endocrine agents that
suppress ERa signaling are highly effective in blocking tumor
growth. However, loss of cellular sensitivity to endocrine therapy
drastically limits the efficacy of the treatment, and substantial
efforts have been put forth to search for new therapy options. In
this study, we demonstrated that the epigenetic regulator EZH2
represents a promising target to overcome tamoxifen resistance,
and indicated that impairing DNA hypermethylation at GREB1
promoter may be associated with the anticancer effects of EZH2-
targeting drugs.
ERa cofactors demonstrate determinative roles in the regula-
tion of ERa-mediated gene expression and further define the
outcome of cellular responses to agonist or antagonist. Our study
disclosed a key component in coordinating the regulatory pro-
teins for proper ERa activity responding to different ligands, and
that is GREB1. It has been demonstrated that GREB1 is required
for binding of other coactivators with ERa upon estrogen stim-
ulation (2). Here we showed that GREB1was also essential for the
formation of inactive ERa complex in response to tamoxifen. It
blocked the associationof key coactivators, such as p300 andCBP,
with tamoxifen-liganded ERa, and subsequently the corepressor
NCoR was recruited to the ERa-associated transcriptional com-
plexes (Fig. 4B and C). This observation is pertinent to a previous
discovery from the quantitative proteomic analysis that GREB1
interacts with estrogen-liganded, but not tamoxifen-liganded ERa
(2). Therefore, GREB1 loses its binding capacity with ERa in the
presence of tamoxifen and fails to bring essential coactivators for
the formation of a functionally active complex. Validation of our
model definitely needs further investigation. Particularly, bio-
chemical evidence is required to demonstrate how other coacti-
vators are restrained from ERa complex by GREB1 and why it is
preferentially occur under antiestrogenic conditions. Understand-
ing these questionswillmost likely provide promising therapeutic
proteins or peptides for the effective treatment of endocrine-
resistant breast cancer.
Multiple studies show that GREB1 is significantly down-
regulated in endocrine-resistant model systems, including cell
lines and xenograft tumors (2, 35), and our work further
confirmed in clinical samples (Fig. 6E). It is largely unknown
how GREB1 gene is suppressed and what factors regulate its
loss. Our data indicates that GREB1 is silenced by EZH2 and
that DNA methylation may account for the epigenetic repres-
sion. Interestingly, we located a CpG-enriched site at GREB1
promoter, which is extensively methylated in endocrine resis-
tant cell lines but devoid of the methylation signal in sensitive
one (Fig. 3D). This striking difference in DNA methylation
pattern is inversely correlated with the expression levels of
GREB1 in clinical cases, highly suggesting that hypermethyla-
tion of this particular CpG site may account for the enduring
downregulation of GREB1 in hormonal therapy–resistant
breast cancer. More critically, methylation signals at some
subsites within GREB1 promoter seem to positively associate
with the pathologic stages of breast tumors, underscoring the
potential clinical relevance of this specific epigenetic mark at
this particular region. All the hypotheses definitely need further
proof, especially in clinical scenarios.
As a histone methyltransferase, EZH2 orchestrates gene expres-
sion that determines cancer cell fate by directly methylating
H3K27 at the promoters of downstream targets (9). Here we
found that H3K27me3 was not remarkably detectable at GREB1
promoter (Supplementary Fig. S6A). Instead, EZH2 modulated
DNAmethylation levels at a specific CpG locus of the region and
concurrent GREB1 expression (Fig. 3E–G; Supplementary Fig.
S6H). However, we are still uncertain whether EZH2-mediated
regulation of DNA methylation in our case is a direct in situ
crosstalk, considering low levels of the repressive histone mark
at the target promoter. We found that expression of DNMT1 and
3Bwas significantly decreased upon EZH2 silencing in TamR cells
(Supplementary Fig. S6I). This result implies a positive control of
methylation intensity at GREB1 promoter by EZH2, and mean-
while stimulates the interest to explore the relationship between
EZH2 and DNA methylation in a genome-wide manner. Inter-
estingly, global DNA hypermethylation has been repeatedly
observed in endocrine-resistant cells, which led to decreased
expressionof central genes including key regulators of ERa activity
(26, 36). These observations are in agreement with the findings
from this study that EZH2 is overexpressed in refractory breast
cancer and it positively regulates the levels and activities of
DNMTs.
In summary, our work reveals a critical epigenetic program that
determines ERa activity as well as cell fate in response to tamox-
ifen treatment (Fig. 7E). In sensitive cells upon short-term expo-
sure of the antiestrogen, the presence of abundant GREB1 protein
fails to recruit essential coactivators to ERa-binding sites and
therefore induces a rapid inactivation of downstream target genes.
However, long-term tamoxifen treatment results in altered activ-
ities of epigenetic enzymes such as EZH2 and DNMTs, which
causes hypermethylation of GREB1 promoter. Maintenance of
GREB1 protein at low levels reprograms ERa-dependent tran-
scriptional machinery and induces a distinct transcriptome that
renders refractory phenotypes in breast cancer cells. Taken togeth-
er, our findings provide a compelling foundation for the clinical
utility of selective EZH2 inhibitors for the treatment of ERþ, TamR
breast cancer that expresses active epigenetic regulator EZH2 and
harbors DNA hypermethylation at the specific CpG locus of
GREB1 promoter region.
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